Clinical practice and implications of biomarker testing in biliary tract cancer: An observational study

Background & Aims: Biliary tract cancers (BTC) are aggressive malignancies with limited treatment options. Owing to the high frequency of actionable genomic alterations (GA) and the availability of targeted therapies, molecular testing has become increasingly important; however, its clinical imp...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Sabrina Welland, Ann-Kristin Zöller, Ilektra A. Mavroeidi, Aurelie Tomczak, Christian Müller, Dong Yawen, Danmei Zhang, Felix Keil, Maria Pangerl, Taotao Zhou, Hossein Taghizadeh, Sebastian Lange, Maximilian N. Kinzler, Kataryna Shmanko, Maryam Barsch, Carolin Zimpel, Angela Djanani, Henning Schulze-Bergkamen, Julius Keyl, Florian Lüke, Thomas Wirth, Michael Dill, Thomas Longerich, Sophia Petschnak, Jens U. Marquardt, Michael Quante, Arndt Weinmann, Dirk Walter, Nicole Pfarr, Gerald Prager, Bernhard Doleschal, Maria A. Gonzalez-Carmona, Rainer Günther, Alexander Scheiter, Stefan Böck, Stephan Bartels, Thomas Gruenberger, Marino Venerito, Christoph Springfeld, Stefan Kasper, Anna Saborowski, Arndt Vogel
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Elsevier 2026-01-01
Ráidu:	JHEP Reports
Fáttát:	panel sequencing molecular targeted therapy precision oncology next-generation sequencing biopsy
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S2589555925003179
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!